Who We Are

Leaders in Complement

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system.

Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available.

The Pursuit of Groundbreaking Science

Founded in 2009 by a small group of entrepreneurs, including a physician-scientist who is our CEO, Apellis was established with the ambition to become the first company to develop a targeted C3 therapy for serious diseases driven by complement. Controlling C3 was viewed as scientifically difficult, if not impossible by many, but the significant unmet needs of patients living with complement-driven diseases inspired our founders’ efforts.

In 2021, our unique approach of targeting C3 was validated with the FDA approval of Apellis’ first therapy. We also are leveraging this science to advance the first potential treatment for geographic atrophy, a leading cause of blindness around the world, and to potentially elevate the standard of care for several serious rare diseases. We believe we are just scratching the surface of what may be possible by targeting C3.

Bold at Our Core

Our company is formed by people who care, are fearless in the face of a challenge, love the work they do, are resourceful, and continually pursue the highest level of scientific integrity. These values guide every decision that we make as we work toward our vision of being a compassionate organization known for its revolutionary science and contributions to humankind.